YB new stock pitches (Fri, Oct 10)

Heartland Express (HTLD), currently trading at $8.41, is positioned to benefit from an ongoing immigration crackdown that has revealed approximately 25% of truck drivers (130 out of 500 inspected) have invalid CDLs, with illegal immigrant drivers previously suppressing freight rates through team driving operations that exceeded legal 11-hour daily limits for solo drivers. The Department of Transportation and Homeland Security joint task force enforcement has caused many illegal drivers to go into hiding out of deportation fears, leading to spot freight rates spiking 50%+ regionally as the industry faces a driver shortage after the longest freight depression in history. A 30% increase in freight rates from $2.30 to $3.00 per mile would swing HTLD from a $43 million GAAP loss to a $41 million profit, increasing revenue from $862 million to $1.08 billion, with a short-term price target of $13.95 (1.00x price-to-sales) and long-term target of $31.01 by end of 2028 (2.0x price-to-sales on $1.2 billion revenue). Key risks include potential inflation from higher freight costs affecting 3.3% of grocery bills, possible 1.1% GDP impact from $324 billion productivity decrease, and the market's current penalty-box treatment of HTLD following two acquisitions, though the company has initiated share buybacks and could benefit from lower interest rates as homebuilding (20% of trucking volume) recovers when rates decline approximately 1.3% under expected new Fed leadership.

Read the full article here. Read time: 8 min

uniQure's (QURE) AMT-130 gene therapy achieved a groundbreaking 75% slowing of Huntington's disease progression over three years (p=0.003) in the high-dose cohort, marking the first therapy to meaningfully alter this fatal disorder's natural course, with key secondary endpoint Total Functional Capacity showing 60% reduction in functional decline (p=0.033) and biomarker cerebrospinal fluid neurofilament-light trending downward versus the typical 10-15% annual increase in untreated patients. The company plans pre-BLA meeting in Q4 2025 and BLA filing in Q1 2026, requesting Priority Review (6-month timeline) and likely pursuing the new Commissioner's National Priority Voucher for 2-month approval of up to five transformative therapies annually. With approximately 100,000 Americans carrying the Huntington's mutation, 40,000 symptomatic, 20,000 diagnosed, and 6,000 initially treatable patients at launch, the therapy's expected $2.5 million pricing represents a $15 billion initial U.S. market opportunity. Historical gene therapy acquisitions like AveXis (Novartis) and Spark (Roche) at 3-5x peak revenues suggest potential acquisition valuations of $15-20 billion ($200-300 per share) versus current ~$4 billion valuation, with logical acquirers including Roche, Biogen, Novartis, Lilly, Pfizer, and Bayer. Key risks include regulatory approval uncertainty, high biotech failure rates, capital intensity, market competition, uncertain revenue until commercialization, and economic downturns disproportionately impacting development-stage biotech stocks.

Read the full article here. Read time: 9 min

Olin Corporation (OLN), the largest US chlor alkali producer, presents a compelling cyclical turnaround opportunity following Warren Buffett's acquisition of OxyChem (the #2 producer) for approximately $10 billion, which implies a $6 billion valuation for OLN based on comparable asset value. The top three players control 70% of the industry, providing oligopolistic dynamics. Despite operating at trough levels, OLN generates a solid 9% free cash flow yield and maintains a 3% dividend while continuing share buybacks. The company carries debt of 3.5x net debt-to-EBITDA but faces no liquidity concerns with no debt maturities until 2029 and bonds trading at 101 to yield 6.2%. The investment thesis centers on OLN being a cyclical turnaround play with direct market validation from Berkshire Hathaway's comparable transaction in the same industry.

Read the full article here. Read time: 1 min